The First Case of Human Hepatic Fasciolosis Presented as Hepatic Pseudotumor Histopathologically Diagnosed in Romania-A Case Report

by Selleckchem | Oct 05 2023

Human hepatic fasciolosis has been reported in 81 countries, some of which are endemic areas. In Europe, case reports from humans were published in Portugal, Spain, France, and Italy. Regarding Romania, we do not have any data on the prevalence of this parasitosis, with the exception of two cases of twins that were born in Romania and diagnosed in the last 37 years in Italy after joining their mother that lived there. We report the case of a patient diagnosed in Romania with chronic fasciolosis, presented as a hepatic pseudotumor that was diagnosed during the histopathological examination of the hepatic lesion. The patient received oral treatment with triclabendazole, two doses of 10 milligrams (mg) per kilogram (kg) of body weight, given 12 h apart, with no side effects during or after the treatment. The evolution of the patient was favorable. In conclusion, even in areas free of human fasciolosis, the presence of an anemic syndrome especially in children, abdominal pain in the upper quadrants, associated or not with other digestive manifestations, even more so associated with eosinophilia in the acute phase, should be carefully evaluated for ruling out a parasitosis such as fasciolosis even in countries where this diagnosis seems unlikely.

Comments:

The passage you provided discusses a case report of a patient diagnosed with chronic fasciolosis in Romania. Fasciolosis is a parasitic infection caused by liver flukes, specifically Fasciola hepatica or Fasciola gigantica. The infection is commonly found in animals such as sheep and cattle, but it can also affect humans.

According to the passage, human hepatic fasciolosis has been reported in 81 countries, some of which are considered endemic areas. In Europe, case reports have been published in Portugal, Spain, France, and Italy. However, there is limited data on the prevalence of fasciolosis in Romania, except for the two cases of twins who were born in Romania but diagnosed in Italy after joining their mother who lived there.

The passage highlights the case of a patient in Romania who was diagnosed with chronic fasciolosis. The diagnosis was made during the histopathological examination of a hepatic lesion that presented as a hepatic pseudotumor. The patient was treated orally with triclabendazole, a medication commonly used to treat fasciolosis. The treatment involved two doses of 10 milligrams per kilogram of body weight, given 12 hours apart. The patient did not experience any side effects during or after the treatment, and their condition improved.

The conclusion drawn from this case report is that even in areas where human fasciolosis is not typically seen, healthcare providers should consider the possibility of this parasitic infection, especially in cases of anemia, upper abdominal pain, and other digestive symptoms, particularly when associated with eosinophilia (an increase in eosinophil count) in the acute phase. The report suggests that fasciolosis should be carefully evaluated as a potential diagnosis, even in countries where it may seem unlikely.